Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Sep
15
Today In Oncology
Adjuvant Alectinib Maintains Quality of Life During 2 Years of Treatment in Resected ALK-Positive NSCLC
High-Risk Prostate Cancer GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT
Extended-Interval Dosing of Tarlatamab Found Safe Effective in SCLC
Favorable Safety Profile Found for Subcutaneous Tarlatamab in ES-SCLC
Genomic Profiles Compared in Early- and Average-Onset Metastatic Colorectal Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo